Direkt zum Inhalt
Merck

Trimethoprim-sulfamethoxazole for bacterial meningitis.

Annals of internal medicine (1984-06-01)
R E Levitz, R Quintiliani
ZUSAMMENFASSUNG

Trimethoprim-sulfamethoxazole has excellent microbiologic activity against most pathogens that produce meningitis; both components of this drug have high penetration into tissues, including the cerebrospinal fluid. Clinical experience shows that trimethoprim-sulfamethoxazole may be beneficial in the treatment of gram-negative bacillary meningitis caused by organisms only moderately susceptible to third-generation cephalosporins (Enterobacter cloacae, Serratia marcescens) or resistant to these antibiotic agents (Pseudomonas cepacia, Acinetobacter). The success of trimethoprim-sulfamethoxazole in the treatment of four patients with Staphylococcus aureus and two patients with Listeria monocytogenes meningitis shows that this drug may also be useful in treating infrequent types of gram-positive meningitis.

MATERIALIEN
Produktnummer
Marke
Produktbeschreibung

Supelco
Sulfamethoxazol
USP
Sulfamethoxazol, United States Pharmacopeia (USP) Reference Standard
Supelco
Sulfamethoxazol, Pharmaceutical Secondary Standard; Certified Reference Material
Supelco
Sulfamethoxazol, VETRANAL®, analytical standard
Sulfamethoxazol, European Pharmacopoeia (EP) Reference Standard
Supelco
Sulfamethoxazol, certified reference material, TraceCERT®, Manufactured by: Sigma-Aldrich Production GmbH, Switzerland